LNC Therapeutics, a Bordeaux, France-based company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, raised €6.5m in Series C funding.
The round was co-led by Seventure Partners with participation from a consortium of historic investors and a family office.
The company will use the funds to continue to expand its development efforts.
Led by Jean-Luc Treillou, CEO, and Sandrine Claus PhD, Chief Scientific Officer, LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials.
The company has raised a total of €16.5m raised so far including €1.5m grants from French BPI and Aquitaine Region.